itamin D Levels in Men with Metabolic Syndrome with or Without Hypogonadism.

ABSTRACT

Aims: To clarify the relation of metabolic syndrome (MS) with or without late-onset hypogonadism (LOH) and vitamin D deficiency in men. Study Design: Consecutive male patients with MS were additionally evaluated for LOH and vitamin D status. Place and Duration of Study Department of Endocrinology, Alexandrovska University hospital, Sofia; between March 2010 and February 2011. Methodology: 99 men were included in the study. Of them 65 had MS and they were divided according to their morning total testosterone (TT) level (cutoff 10.4 nmol/l) into two groups MS-LOH (N=21) and MS-noLOH (N=44). The control group consisted of 34 men without MS and LOH. Vitamin D levels were measured using electrochemiluminiscence immunoassay. Results: MS men were at mean age (±SD) = 50.4±9.6 years and had TT = 13.6±5.4 nmol/l. The control group was at age = 51.5±6.4 years (compared to MS NS) and had TT = 17.9±5.6 nmol/l (compared to MS P< .001). MS-LOH sub-group had age 47.9±10.5 years and TT = 8.1±1.5 nmol/l; MS-NoLOH sub-group – age 51.6±9.1 years, TT = 16.3±4.5 nmol/l. The levels of vitamin D were higher in the controls – 27.9±12.0 ng/ml compared to the MS – 16.2±9.1 ng/ml (P< .001). There was no difference in 25(OH)D between MS-LOH – 17.4±10.9 ng/ml and MS-NoLOH – 15.6±8.2 ng/ml sub-groups. They both differed from the control group (P< .001). There was a negative relationship between 25(OH)D and BMI in all patients (rho= -0,344, P< .001) and in the MS-LOH group (rho= -0,439, P< .05). Similar relationship was found between vitamin D and waist circumference (respectively rho= -0,459, P< .001; rho= -0,553, P= .011). Much smaller in strength but significant correlation was the one between vitamin D levels and Aging Male Score in all patients (rho= -0,254, P< .05). Conclusion: There are no differences in vitamin-D levels when comparing metabolic syndrome patients with and without late onset hypogonadism.